370 related articles for article (PubMed ID: 9932083)
1. [Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials].
Mitry E; Ducreux M; Rougier P
Bull Cancer; 1998 Dec; Spec No():38-42. PubMed ID: 9932083
[TBL] [Abstract][Full Text] [Related]
2. [Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials].
Van Cutsem E; Peeters M
Bull Cancer; 1998 Dec; Spec No():33-7. PubMed ID: 9932082
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.
Van Cutsem E; Blijham GH
Semin Oncol; 1999 Feb; 26(1 Suppl 5):13-20. PubMed ID: 10213010
[TBL] [Abstract][Full Text] [Related]
4. A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group.
Cunningham D; Glimelius B
Semin Oncol; 1999 Feb; 26(1 Suppl 5):6-12. PubMed ID: 10213009
[TBL] [Abstract][Full Text] [Related]
5. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.
Rougier P; Van Cutsem E; Bajetta E; Niederle N; Possinger K; Labianca R; Navarro M; Morant R; Bleiberg H; Wils J; Awad L; Herait P; Jacques C
Lancet; 1998 Oct; 352(9138):1407-12. PubMed ID: 9807986
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
Freyer G; Rougier P; Bugat R; Droz JP; Marty M; Bleiberg H; Mignard D; Awad L; Herait P; Culine S; Trillet-Lenoir V
Br J Cancer; 2000 Aug; 83(4):431-7. PubMed ID: 10945486
[TBL] [Abstract][Full Text] [Related]
7. [Irinotecan in combination for colon cancer].
Ducreux M; Gil-Delgado M; André T; Ychou M; de Gramond A; Khayat D
Bull Cancer; 1998 Dec; Spec No():43-6. PubMed ID: 9932084
[TBL] [Abstract][Full Text] [Related]
8. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.
Cunningham D; Pyrhönen S; James RD; Punt CJ; Hickish TF; Heikkila R; Johannesen TB; Starkhammar H; Topham CA; Awad L; Jacques C; Herait P
Lancet; 1998 Oct; 352(9138):1413-8. PubMed ID: 9807987
[TBL] [Abstract][Full Text] [Related]
9. [Clinical activity spectrum of irinotecan].
Cottu PH; Extra JM; Lerebours F; Espie M; Marty M
Bull Cancer; 1998 Dec; Spec No():21-5. PubMed ID: 9932080
[TBL] [Abstract][Full Text] [Related]
10. Comparing irinotecan with best supportive care and infusional 5-fluorouracil: a critical evaluation of the results of two randomized phase III trials.
Wilke HJ
Semin Oncol; 1999 Feb; 26(1 Suppl 5):21-3. PubMed ID: 10213011
[TBL] [Abstract][Full Text] [Related]
11. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer.
Fuchs CS; Moore MR; Harker G; Villa L; Rinaldi D; Hecht JR
J Clin Oncol; 2003 Mar; 21(5):807-14. PubMed ID: 12610178
[TBL] [Abstract][Full Text] [Related]
12. Setting a new standard--irinotecan (Campto) in the second-line therapy of colorectal cancer: final results of two phase III studies and implications for clinical practice.
Cunningham D
Semin Oncol; 1999 Feb; 26(1 Suppl 5):1-5. PubMed ID: 10213008
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan: toward clinical end points in drug development.
Pazdur R
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):13-21. PubMed ID: 9726086
[TBL] [Abstract][Full Text] [Related]
14. Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis.
Landre T; Uzzan B; Nicolas P; Aparicio T; Zelek L; Mary F; Taleb C; Des Guetz G
Int J Colorectal Dis; 2015 Oct; 30(10):1305-10. PubMed ID: 26099322
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan in the treatment of colorectal cancer.
Fuchs C; Mitchell EP; Hoff PM
Cancer Treat Rev; 2006 Nov; 32(7):491-503. PubMed ID: 16959432
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy for colorectal cancer.
Goyle S; Maraveyas A
Dig Surg; 2005; 22(6):401-14. PubMed ID: 16479107
[TBL] [Abstract][Full Text] [Related]
17. [[Irinotecan--experience with second-line treatment in advanced colorectal cancer] ].
Kristó K; Izsó J; Balatoni G; Lohinszky J; Farczádi E; Szántó J; Kofi AP; Pintér T
Orv Hetil; 2000 Aug; 141(33):1817-20. PubMed ID: 10979311
[TBL] [Abstract][Full Text] [Related]
18. Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure.
Schmitt C; Blijham G; Jolain B; Rougier P; Van Cutsem E
Anticancer Drugs; 1999 Jul; 10(6):617-23. PubMed ID: 10885910
[TBL] [Abstract][Full Text] [Related]
19. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Thuss-Patience PC; Kretzschmar A; Bichev D; Deist T; Hinke A; Breithaupt K; Dogan Y; Gebauer B; Schumacher G; Reichardt P
Eur J Cancer; 2011 Oct; 47(15):2306-14. PubMed ID: 21742485
[TBL] [Abstract][Full Text] [Related]
20. Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial.
Gibbs P; Clingan PR; Ganju V; Strickland AH; Wong SS; Tebbutt NC; Underhill CR; Fox RM; Clavant SP; Leung J; Pho M; Brown TJ
Cancer Chemother Pharmacol; 2011 Jan; 67(1):153-63. PubMed ID: 20333384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]